نتائج البحث - Sin‐Ho Jung

تنقيح النتائج
  1. 1
    Sample size for FDR-control in microarray data analysis

    Sample size for FDR-control in microarray data analysis حسب Sin‐Ho Jung

    منشور في 2005
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Sample size calculation for multiple testing in microarray data analysis

    Sample size calculation for multiple testing in microarray data analysis حسب Sin‐Ho Jung, Heejung Bang, S. Stanley Young

    منشور في 2004
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  3. 3
    Photoreceptor Layer Thinning over Drusen in Eyes with Age-Related Macular Degeneration Imaged In Vivo with Spectral-Domain Optical Coherence Tomography

    Photoreceptor Layer Thinning over Drusen in Eyes with Age-Related Macular Degeneration Imaged In Vivo with Spectral-Domain Optical Coherence Tomography حسب Stefanie Schuman, Anjum F. Koreishi, Sina Farsiu, Sin‐Ho Jung, Joseph A. Izatt, Cynthia A. Toth

    منشور في 2009
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  4. 4
    Randomised, double-blind, placebo-controlled trial of Probiotics To Eliminate COVID-19 Transmission in Exposed Household Contacts (PROTECT-EHC): a clinical trial protocol

    Randomised, double-blind, placebo-controlled trial of Probiotics To Eliminate COVID-19 Transmission in Exposed Household Contacts (PROTECT-EHC): a clinical trial protocol حسب Helen Tang, Lauren Bohannon, M. Lew, David Jensen, Sin‐Ho Jung, Aaron T. Zhao, Anthony D. Sung, Paul E. Wischmeyer

    منشور في 2021
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  5. 5
    Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness

    Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront... حسب M. S. Czuczman, John P. Leonard, Sin‐Ho Jung, Jeffrey L. Johnson, Eric D. Hsi, John C. Byrd, Bruce D. Cheson

    منشور في 2012
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  6. 6
    Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non–Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial

    Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non–Small-Cell Lung Cancer: A Biomarker-Stratified Randomize... حسب Jong‐Mu Sun, Jin Seok Ahn, Sin‐Ho Jung, Jiyu Sun, Sang Yun Ha, Joungho Han, Keunchil Park, Myung‐Ju Ahn

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  7. 7
    Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma

    Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma حسب Jeffrey T. Schleusener, Henry D. Tazelaar, Sin‐Ho Jung, S. Stephen, J. Peter, Jeffrey L. Myers, Edward T. Creagan, Richard M. Goldberg, Robert F. Marschke

    منشور في 1996
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  8. 8
    Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202)

    Intensive Chemotherapy and Immunotherapy in Patients With Newly Diagnosed Primary CNS Lymphoma: CALGB 50202 (Alliance 50202) حسب James L. Rubenstein, Eric D. Hsi, Jeffrey L. Johnson, Sin‐Ho Jung, Megan O. Nakashima, Barbara Grant, Bruce D. Cheson, Lawrence D. Kaplan

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  9. 9
    Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B

    Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B حسب Won Sohn, Ju‐Yeon Cho, Ji Hoon Kim, Jung Il Lee, Hyung Joon Kim, Min‐Ah Woo, Sin‐Ho Jung, Yong‐Han Paik

    منشور في 2017
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  10. 10
    Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism

    Serious pulmonary toxicity in patients with Hodgkin’s lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism... حسب Kristie A. Blum, Sin‐Ho Jung, Jeffrey L. Johnson, Thomas S. Lin, Eric D. Hsi, David Lucas, John C. Byrd, Bruce D. Cheson, Nancy L. Bartlett

    منشور في 2010
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  11. 11
    Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance)

    Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance) حسب John P. Leonard, Sin‐Ho Jung, Jeffrey L. Johnson, Brandelyn N. Pitcher, Nancy L. Bartlett, Kristie A. Blum, Myron S. Czuczman, Jeffrey K. Giguere, Bruce D. Cheson

    منشور في 2015
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  12. 12
    A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701

    A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701 حسب Barbara Grant, Sin‐Ho Jung, Jeffrey L. Johnson, Lale Kostakoğlu, Eric D. Hsi, John C. Byrd, Jeffrey A. Jones, John P. Leonard, Sabrina Martín, Bruce D. Cheson

    منشور في 2013
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  13. 13
    Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study

    Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correl... حسب Eric D. Hsi, Sin‐Ho Jung, Raymond Lai, Jeffrey L. Johnson, James R. Cook, Dan Jones, Sven deVos, Bruce D. Cheson, Lloyd E. Damon, Jonathan W. Said

    منشور في 2008
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  14. 14
    Clinical relevance of procalcitonin and C-reactive protein as infection markers in renal impairment: a cross-sectional study

    Clinical relevance of procalcitonin and C-reactive protein as infection markers in renal impairment: a cross-sectional study حسب Ji Hyeon Park, Do Hee Kim, Hye Ryoun Jang, Min‐Ji Kim, Sin‐Ho Jung, Jung Eun Lee, Wooseong Huh, Yoon-Goo Kim, Dae Joong Kim, Ha Young Oh

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  15. 15
    Alveolar Macrophages from Overweight/Obese Subjects with Asthma Demonstrate a Proinflammatory Phenotype

    Alveolar Macrophages from Overweight/Obese Subjects with Asthma Demonstrate a Proinflammatory Phenotype حسب Njira Lugogo, John W. Hollingsworth, Druhan L. Howell, Loretta G. Que, Dave Francisco, Tony D. Church, Erin N. Potts-Kant, Jennifer L. Ingram, Ying Wang, Sin‐Ho Jung, Monica Kraft

    منشور في 2012
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  16. 16
    Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma

    Phase I trial of intratumoral PVSRIPO in patients with unresectable, treatment-refractory melanoma حسب Georgia M. Beasley, Smita K. Nair, Norma E. Farrow, Karenia Landa, Maria Angelica Selim, Carol Ann Wiggs, Sin‐Ho Jung, Darell D. Bigner, Andrea Kelly, Matthias Gromeier, April K.S. Salama

    منشور في 2021
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  17. 17
    Interim [<sup>18</sup>F]fluorodeoxyglucose positron emission tomography imaging in stage I–II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?

    Interim [<sup>18</sup>F]fluorodeoxyglucose positron emission tomography imaging in stage I–II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and comp... حسب Lale Kostakoğlu, Heiko Schöder, Jeffrey L. Johnson, Nathan C. Hall, Lawrence H. Schwartz, David J. Straus, Ann S. LaCasce, Sin‐Ho Jung, Nancy L. Bartlett, George P. Canellos, Bruce D. Cheson

    منشور في 2012
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  18. 18
    CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells

    CALGB 150905 (Alliance): Rituximab Broadens the Antilymphoma Response by Activating Unlicensed NK Cells حسب Juan Du, Sandra López‐Vergès, Brandelyn N. Pitcher, Jeffrey L. Johnson, Sin‐Ho Jung, Lili Zhou, Katharine C. Hsu, Myron S. Czuczman, Bruce D. Cheson, Lawrence Kaplan, Lewis L. Lanier, Jeffrey M. Venstrom

    منشور في 2014
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  19. 19
    A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance)

    A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin’s lymphoma (NHL): CALGB 50803 (Alliance) حسب Peter W. Martin, Sin‐Ho Jung, Brandelyn N. Pitcher, Nancy L. Bartlett, Kristie A. Blum, M. Tracie Shea, Eric D. Hsi, Jia Ruan, Scott E. Smith, John P. Leonard, Bruce D. Cheson

    منشور في 2017
    احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  20. 20
    Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non–small cell lung cancer

    Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non–small cell lung cancer حسب Carolyn E. Reed, David H. Harpole, Katherine E. Posther, Sandra Woolson, Robert J. Downey, Bryan F. Meyers, Robert T. Heelan, Homer A. Macapinlac, Sin‐Ho Jung, Gerard A. Silvestri, Barry A. Siegel, Valerie W. Rusch

    منشور في 2003
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: